Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
timdarpacept
- Development stage
- Phase 3
- Lead developer
- ImmuneOnco
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Timdarpacept (formerly known as IMM01 or SIRPαFc) is a recombinant fusion protein developed by ImmuneOnco Biopharma. It targets the CD47 antigen and acts as an immune checkpoint inhibitor by blocking the "don't eat me" signal on tumor cells. This blockade enables macrophage-mediated phagocytosis of cancer cells and enhances anti-tumor immunity through antibody-dependent cellular cytotoxicity (ADCC), stimulation of phagocytes, and T lymphocyte activation. Timdarpacept is being investigated primarily for hematologic malignancies such as chronic myelomonocytic leukemia (CMML), myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and solid tumors[1][5][6].
- Brand names
- timdarpacept
- Other names
- IMM01IMM-01IMM 01SIRPαFc
02
Targets
CD47 (Cluster of Differentiation 47)
Beyond the preview
Go deeper on timdarpacept.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on timdarpacept.